Elastolytic activity of alveolar macrophages in chronic bronchitis: comparison of current and former smokers

S O’Neill, JS Prichard

Department of Clinical Medicine, Trinity College, Dublin, St James’s Hospital, Dublin

ABSTRACT We have compared the macrophage elastolytic activity of a group of current and former smokers with irreversible airflow obstruction. Elastolytic activity was determined in an initial bronchoalveolar lavage cell population and in alveolar macrophages cultured for three days, to investigate whether enhanced macrophage elastolytic activity alone is a determining factor in the susceptibility of some smokers to obstructive lung disease. Twenty current smokers and 12 former smokers who had abstained from smoking for at least three years were studied. All patients had spirometric evidence of irreversible airflow obstruction. Current smokers had a cell yield (mean ± SD) of 138.7 ± 36.4 × 10⁶ cells (alveolar macrophages 94.2% ± 2.1%) compared with 31.4 ± 14.1 × 10⁶ cells (macrophages 86.5% ± 4.7%) in former smokers. Elastolytic activity in the initial lavage cell population from current and former smokers, measured with the synthetic elastase substrate succinyl-L-alanyl-L alanyl-L-alanine-p-nitroanilide, and expressed as the equivalent of 1 µg of porcine pancreatic elastase, was respectively 0.113 ± 0.003 and 0.096 ± 0.004 µg pancreatic elastase/mg cell protein. After three days in culture macrophage elastolytic activity in the current and former smokers’ cells was respectively 0.107 ± 0.006 and 0.011 ± 0.001 µg pancreatic elastase/mg cell protein (p < 0.05). The elastase activity of the cultured alveolar macrophages from five current smokers had the inhibitor profile of a metalloproteinase.

Our results indicate that enhanced macrophage elastolytic activity alone is not a determining factor in the susceptibility of some smokers to develop obstructive lung disease.

The proteolytic theory of the pathogenesis of emphysema suggests that the balance between elastase activity and its inhibition is altered, in certain susceptible patients, by exogenous factors such as smoking or endogenous factors such as α₁-antiproteinase deficiency, with resultant elastinolysis. Alveolar macrophages may be important in the pathogenesis of centrilobular emphysema of cigarette smokers for the following reasons. An expanded alveolar macrophage population is found in the region of the terminal bronchioles in young smokers. In normal subjects bronchoalveolar lavage yields four to five times more cells in smokers than in non-smokers, 95% of these cells being alveolar macrophages. Alveolar macrophages from smokers show greater elastolytic activity during in vitro culture and release more elastolytic activity into conditioned media in vitro than do macrophages from non-smoking normal subjects.

All previous studies, however, have compared elastolytic activity of alveolar macrophages from normal smokers and non-smokers. As only a proportion of smokers will develop significant lung disease, we thought that studies of a group of current and former smokers with obstructive lung disease were necessary to explore the question of whether enhanced macrophage elastolytic activity alone is a determining factor in the susceptibility of some smokers to lung disease.

Methods

We studied 20 current smokers and 12 former smokers who had abstained from smoking for at least three years (mean 5.1, range 3–10.2 years). Both the current and the former smokers had consumed at least 20 cigarettes a day for at least 10 years. All had grade 3 or 4 dyspnoea and currently fulfilled criteria for chronic bronchitis. Spirometry
Macrophage elastase and smoking

(played with a Vitalograph spirometer in the sitting position) indicated irreversible airflow obstruction (FEV, and FEV/FVC ratio less than 60% of predicted, with less than 10% increase in FEV 15 minutes after inhalation of 200 μg salbutamol on three separate occasions) in all patients.

The mean FEV 1 was 42.7% (SD ±6.2%) of the predicted value. The mean age of the patients was 59.9 years and the range 42-68 years. All patients gave informed consent to the study, which had been approved by the hospital ethics committee. They were all being investigated because of a solitary pulmonary nodule and none had noted recent change in sputum characteristics or degree of dyspnoea or none had fever or leucocytosis. Lavage was performed on the lung opposite to the nodule.

Bronchoalveolar lavage was performed with 50-ml aliquots of sterile, warm (37°C) phosphate-buffered normal saline to a total of 300 ml, through the tip of a fibreoptic bronchoscope wedged in a subsegmental bronchus of a lower lobe. The fluid recovered (about half of the instilled volume) was placed in sterile, plastic, conical centrifuge tubes, chilled to 4°C, and centrifuged at 1000 g for 10 minutes, within 30 minutes of aspiration. The cells were washed three times with Hank's Balanced Salt Solution. A portion of cells was suspended in the Hank's Solution at a concentration of about 1.0 x 10⁷ cells/ml and was used directly for enzyme assays and differential cell counts (made from both Wright's and non-specific-esterase-stained preparations with α-naphthyl butyrate).

The remaining cells were cultured in Neuman-Tytell serum-free medium (Gibco-Biocult), 1-ml suspensions in 35 mm petri dishes (Falcon) being used. After three hours the cultures were washed to remove non-adherent cells, and fresh medium was added. The medium was also changed at 24 and 48 hours. Cell viability was assessed by measuring release of lactate dehydrogenase into the medium.

Tissue culture medium was prepared for assay by centrifugation at 500 g for 10 minutes and dialysis of 4-ml aliquots against 10 mmol/l tris-HCl (pH 7.6) containing 1 mmol/l CaCl₂, for 48 hours, after which the material was lyophilised. Before assay the lyophilisate was reconstituted with cold distilled water to 5% of the original volume.

Cultured cells were prepared for assay by scraping of adherent macrophages from dishes into Hank's Solution, and membranes were disrupted by sonification for 1 minute at 0°C. Myeloperoxidase activity was used as an index of contamination by polymorphonuclear leucocytes, because the enzyme is not found in human lymphocytes and cannot be detected in cultured alveolar macrophages.

Elastolytic activity was measured by hydrolysis of succinyl-l-alanyl-l-alanyl-l-alanine-p-nitroanilide (SLAPN, Bachem Feinchemikalien AG, Bubendorf, Switzerland), a synthetic substrate which detects amidolytic activity and is probably specific for neutrophil, pancreatic, and macrophage elastase.

Hydrolysis of 1-35 mg of SLAPN with 20 μl of cell lysates or tissue culture medium was carried out at 37°C in 3 ml of 0.2 mol/l tris HCl with 50 mmol/l CaCl₂, and change in absorbance was measured at 410 nm. Standards of porcine pancreatic elastase (Sigma Chemical Co) were run simultaneously for comparison. All activity is expressed as the equivalent of μg pancreatic elastase per mg of cell protein. Protein was assayed by a Lowry procedure. Elastase inhibition studies were performed on five of the current smokers with the serine proteinase inhibitors soya-bean trypsin inhibitor and phenylmethylsulphonyl fluoride and the metalloproteinase inhibitor EDTA (all inhibitors purchased from Sigma Chemical Co). Samples were preincubated for 30 minutes at 37°C (pH 7-8) with the inhibitor before SLAPN was added, and the assay was then performed as previously described. The terms elastase and elastolytic activity, where they are used in the context of our present findings, indicate activity measured by this assay.

Statistical data are presented as the means ± 1 standard deviation. Student's t test for paired or unpaired variables was used to determine the significance of any difference.

Results

Current smokers had a mean cell yield of 138.7 ± 36.4 x 10⁶, in contrast to 31.4 ± 14.1 x 10⁶ in former smokers (p < 0.01). The mean percentage of alveolar macrophages was 94.2 ± 2.1 in the current smokers and 86.5 ± 4.7 in the former smokers. Lymphocytes comprised 3.0% ± 3.6% and 10.3% ± 4.9% respectively and polymorphonuclear leukocytes 2.8% ± 2.7% and 3.2% ± 3.8%.

Data on elastolytic activity with SLAPN are presented in the figure. The initial elastase activity in cells from 20 current smokers and 12 former smokers, all of whom had detectable activity, was equivalent to 0.113 ± 0.003 and 0.096 ± 0.004 μg pancreatic elastase/mg of cell protein respectively; these values are not significantly different. Unfortunately, sufficient cells were available from only 10 of the former smokers for culture studies. After culture of the lavaged cells from both the groups studied for three days no polymorphonuclear leucocytes were detected by light microscopy (Wright's stain of cover slip preparation), no myeloperoxidase activity was detected in either the cells or the final culture
Concentration and inhibitor activity of elastase expressed in culture medium. 1.0 fluoride and 5.0 (mmol/l) in the medium, and at 48 hours 30% of the total lactate dehydrogenase activity was extracellular. The elastase activity in the cultured macrophages from current smokers and former smokers was equivalent to 0.107 ± 0.006 and 0.011 ± 0.001 μg pancreatic elastase/mg cell protein respectively (p < 0.05). The difference reflects the negligible elastolytic activity of cultured alveolar macrophages from former smokers, four of whom had no detectable activity. The levels of elastolytic activity were similar to those found previously in smoking and non-smoking normal subjects and may reflect an enhanced biosynthetic activity of smokers’ alveolar macrophages.

The extracellular elastase activity in the final tissue culture medium was measured. No activity was detected in the former smokers. The current smokers had a mean activity of 0.012 ± 0.001 μg pancreatic elastase/mg of cell protein.

The inhibition profile of the SLAPN elastase activity of the cultured alveolar macrophages from five current smokers is given in the table. The elastase activity has the features of a metalloproteinase, as indicated by inhibition by EDTA and by the lack of inhibition with phenylmethanesulphonyl fluoride and soya-bean trypsin inhibitor.

### Discussion

These observations suggest that cessation of smoking for at least three years in patients with chronic bronchitis is associated with reduction in total lavage cell counts and in elastolytic activity of an in vitro culture of alveolar macrophages.

The total and differential cell counts obtained by lung lavage in our groups of current and former smokers follow a pattern similar to that previously observed in normal smoking and non-smoking subjects. There was no significant difference between current and former smokers in elastolytic activity per mg cell protein of the initial lavage cell population, although the greater number of cells (four to five times more) in the current smokers imposes a potentially greater elastase burden on the lungs of these subjects. The alveolar macrophages from current smokers, after in vitro culture for three days, showed a degree of elastolytic activity similar to that found in the initial lavage cell population and released SLAPN elastase activity into the culture medium that had the characteristics of a metalloproteinase rather than a serine proteinase. In contrast, the cultured alveolar macrophages from former smokers showed a negligible degree of elastolytic activity, about 10% of the activity of the initial lavage cell population, and released no SLAPN elastase activity into the culture medium. The inhibition profile of the SLAPN elastase activity of cultured alveolar macrophages from former smokers was not determined. Previous studies in smoking and non-smoking normal subjects have shown similar degrees of elastolytic activity, with a decline in the SLAPN elastase activity of non-smokers’ macrophages to negligible levels after in vitro culture for three days. The failure of smokers’ macrophages to show this decline may be due to an enhanced biosynthetic activity in their macrophages. It could also be argued that the decline in elastolytic activity...
activity represents metabolism of internal neutrophil elastase, although without inhibition studies of the SLAPN elastase activity of the macrophages of former smokers before culture this remains uncertain.

Our results are similar to those in normal subjects studied previously and suggest that enhanced macrophage elastolytic activity on its own does not explain why only some smokers develop obstructive lung disease. This study examines only one facet of a potential proteinase-antiproteinase imbalance. An expanded alveolar macrophage population with enhanced elastolytic activity may yet be shown to be important in the pathogenesis of emphysema, acting in concert with neutrophil elastase to induce elastinolysis in susceptible patients with smoking-induced functional α1-proteinase inhibitor deficiency. Support for this idea comes from the following observations: normal smokers have increased numbers of neutrophils in their bronchoalveolar fluid, thought to be secondary to release of neutrophil chemotactic factors by smoke-stimulated alveolar macrophages; cigarette smoke condensate can induce elastase release from neutrophils both by producing cytotoxic reactions and by stimulating secretion from viable cells; functional α1-proteinase inhibitor deficiency has been found in the bronchoalveolar fluid of normal smokers (about 60% of the activity of non-smoking controls). Further studies which include patients with established obstructive lung disease, in addition to normal smokers and non-smokers, are necessary for exploring the proteolytic theory of the pathogenesis of emphysema in susceptible smoking subjects.

The authors wish to thank the Wellcome Foundation, which through a grant to Trinity College, Dublin, provided support for JSP's salary and for the purchase of equipment and reagents.

References

2 Reynolds HY, Newball HH. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974;84:559–73.
Elastolytic activity of alveolar macrophages in chronic bronchitis: comparison of current and former smokers.
S O'Neill and J S Prichard

Thorax 1983 38: 356-359
doi: 10.1136/thx.38.5.356

Updated information and services can be found at:
http://thorax.bmj.com/content/38/5/356

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/